BASEL, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) — BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today the reporting of its Full Year 2025 financial results, along with a business update and the hosting of an investor, analyst and media conference call.
BioVersys to Report Its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
